CClinicalTrials.gg
CompletedNCT04242251SPARKLE2Updated Apr 3, 2024

Novel Palliative Care Model for Advanced Cancer Patients: A Randomized Controlled Trial Study

An interventional study of SPARKLE Model of care in Cancer, sponsored by National Cancer Centre, Singapore. Completed at 1 site in Singapore. Open to participants aged 21 Years to 120 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-03.

Sponsored by National Cancer Centre, Singapore · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
239
Allocation
Randomized
Ages
21 Years to 120 Years
Sex
All
01

Study summary

This is a randomized controlled trial of the 'Supportive and Palliative care Review Kit in Locations Everywhere' (SPARKLE) intervention, an outpatient-based model of early palliative care. The SPARKLE intervention comprises regular symptom monitoring using questionnaires, early identification and prompt treatment of problems identified. Proactive screening for problems facilitates earlier palliative care interventions for advanced cancer patients, whenever needs arise.

Read the detailed description

This is a randomized controlled trial to compare clinical outcomes between advanced cancer patients receiving and not receiving care from the SPARKLE care model, in addition to current oncologic-led palliative care model. The hypothesis is that the SPARKLE care model results in a) improved quality of life of both advanced cancer patients and their caregivers, and b) reduced acute healthcare utilization and costs by these patients.

Primary Study Aim: To determine the incremental effect of SPARKLE in addition to usual oncologist-led care on quality of life of advanced cancer patients. Patients' quality of life will be measured at baseline before randomization and 16 weeks after randomization using the Functional Assessment of Cancer Therapy - General (FACT-G).

Secondary Study Aim 1: To determine the incremental effect of SPARKLE in addition to usual oncologist-led care on caregivers' quality of life. Caregiver quality of life will be measured at baseline before randomization and 16 weeks after randomization using the Singapore Caregiver Quality of Life Scale (SCQOLS), which was validated among caregivers of advanced cancer patients in Singapore.17 The PI was part of the team, led by the applicant's mentor, that developed the SCQOLS.

Secondary Study Aim 2: To determine the effect of SPARKLE in addition to usual oncologist-led care on healthcare utilization and total healthcare costs, including the costs of delivering SPARKLE, from randomization until death. Healthcare utilization and cost data will be extracted from medical and billing data. SPARKLE costs will be captured prospectively using an Activity Based Costing Approach. The study hypothesis is that per capita healthcare costs will be lower in the SPARKLE model due to fewer admissions and shorter hospital lengths of stay when admitted.

A prospective randomized controlled trial design will be used to test the effectiveness of the SPARKLE model. The recruitment target is 240 patients with advanced cancers, defined as stage 4 solid tumors including lung, colorectal, nasopharyngeal and pancreatic cancers. Eligible participants are randomized to usual care or SPARKLE intervention group using randomized permuted blocks method generated by an independent statistician, with block size kept unknown to the clinical investigators/site personnel. A total of 240 caregivers will be recruited.

The study will take place in the National Cancer Centre of Singapore (NCCS).

02

Conditions studied

  • Cancer

Keywords

  • Palliative Care
  • Cancer
  • Health Services Research
03

In context

Lead sponsor

National Cancer Centre, Singapore is the lead sponsor of 116 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Patient participants Inclusion Criteria:

  • Adult aged 21 and above
  • Stage 4 solid tumor

Patient participants Exclusion Criteria:

  • Unable to complete patient-reported outcome measures
  • Already under the care of an existing palliative care service

Caregiver participants Inclusion Criteria:

  • Adult aged 21 and above

Caregiver participants Exclusion Criteria:

  • Unable to complete Singapore Caregiver Quality of Life Scale questionnaire
  • Employed caregiver to patient participants
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
239 participants (actual)

Study arms

  • No intervention
    Usual Care

    Management by primary oncologist. Referral to existing palliative care service initiated by primary oncologist if needed.

  • Experimental
    SPARKLE intervention group

    Regular symptom monitoring and treatment of problems identified. Referral to existing palliative care services can also be initiated by the SPARKLE nurse if identified problems require follow up.

    Other: SPARKLE Model of care

Interventions

  • OtherSPARKLE Model of care

    Patients will receive the SPARKLE model of care in addition to usual oncologist-led care. The SPARKLE model will be led by a palliative medicine doctor and administered by nurses and staff without specific nursing or medical training. It utilizes a stepped care approach where all patients will initially have low-intensity model focused on weekly symptom monitoring through a patient-reported questionnaire. If any problems are identified, then patients step up to a higher-intensity care model where a nurse will conduct a phone assessment of the symptom problems. If the presence of symptoms is confirmed, patients step up again to an even higher-intensity care model where treatment of symptoms will be initiated by the SPARKLE nurse, depending on the severity of the problems. If the symptoms are not fully resolved, the patients will then step up to the highest-intensity care model which is an existing palliative care service- either palliative care outpatient clinic or home hospice.

06

What researchers measure

Primary outcomes

  1. Functional Assessment of Cancer Therapy- General

    Quality of life is scored on a scale of 0 to 108, with higher scores indicating better outcomes

    Time frame: 16 weeks

Secondary outcomes

  1. Singapore Caregiver Quality of Life Scale

    Caregiver quality of life is scored on a scale of 0 to 100, with higher scores indicating better outcomes

    Time frame: 16 weeks

07

Study locations

1 site
  • National Cancer Centre Singapore
    Singapore, 169610, Singapore
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04242251
Lead sponsor
National Cancer Centre, Singapore
Collaborators
Ministry of Health, Singapore
Responsible party
Sponsor
First posted
Jan 27, 2020
Start date
Feb 8, 2021
Primary completion
Apr 30, 2023
Completion
Jan 31, 2024
Last update
Apr 3, 2024

Study contacts

Grace M Yang, MRCP
principal investigator · Consultant

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion